Johnson & Johnson (JNJ) is a leading drug manufacturers - general business based in the US. It opened the day at $0.00 after a previous close of $0.00. During the day the price has varied from a low of $0.00 to a high of $0.00. The latest price was $0.00 (25 minute delay). Johnson & Johnson is listed on the NYSE and employs 138,100 staff. All prices are listed in US Dollars.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Johnson & Johnson stock price (NYSE: JNJ)
Use our graph to track the performance of JNJ stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Johnson & Johnson stock undervalued or overvalued?
Valuing Johnson & Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson & Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson & Johnson's P/E ratio
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Johnson & Johnson shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson & Johnson's PEG ratio
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1181. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson & Johnson's EBITDA
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.9 billion.
The EBITDA is a measure of a Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
Johnson & Johnson financials
Revenue TTM
$92.1 billion
Operating margin TTM
30.2%
Gross profit TTM
$63 billion
Return on assets TTM
8.26%
Return on equity TTM
33.62%
Profit margin
27.26%
Book value
$32.95
Market Capitalization
$494.7 billion
TTM: trailing 12 months
Johnson & Johnson share dividends
Dividend payout ratio: 42.3% of net profits
Recently Johnson & Johnson has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson & Johnson shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Johnson & Johnson's case, that would currently equate to about $5.08 per share.
While Johnson & Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson & Johnson may be investing much of the rest of its net profits in future growth.
Johnson & Johnson's most recent dividend payout was on 8 December 2025. The latest dividend was paid out to all shareholders who bought their shares by 24 November 2025 (the "ex-dividend date").
Have Johnson & Johnson's shares ever split?
Johnson & Johnson's shares were
split on a 2:1 basis on 12 June 2001
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson & Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson & Johnson shares which in turn could have impacted Johnson & Johnson's share price.
Johnson & Johnson share price volatility
Over the last 12 months, Johnson & Johnson's shares have ranged in value from as little as $136.504 up to $207.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson & Johnson's is 0.358. This would suggest that Johnson & Johnson's shares are less volatile than average (for this exchange).
Johnson & Johnson overview
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Frequently asked questions
null What percentage of Johnson & Johnson is owned by insiders or institutions? Currently 0.058% of Johnson & Johnson shares are held by insiders and 74.967% by institutions.How many people work for Johnson & Johnson? Latest data suggests 138,100 work at Johnson & Johnson.When does the fiscal year end for Johnson & Johnson? Johnson & Johnson's fiscal year ends in December.Where is Johnson & Johnson based? Johnson & Johnson's address is: One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933What is Johnson & Johnson's ISIN number? Johnson & Johnson's international securities identification number is: US4781601046What is Johnson & Johnson's CUSIP number? Johnson & Johnson's Committee on Uniform Securities Identification Procedures number is: 478160104
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
